Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer

Breast Cancer Clinical Trial

— CAP7/7  

Official title:

Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02028494
• Other study ID #: SLACOM Cap 7/7
• Status: Recruiting
• Phase: N/A
• Start date: August 2013
• Est. completion date: March 2019

Study information

• Verified date: September 2018
• Source: Latin American & Caribbean Society of Medical Oncology
• Contact: Daniel Campos, MD
• Phone: +5491144204242
• Email: dcampos[@]slacom.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the efficacy of a novel schedule of an oral anticancer drug, capecitabine, in patients with metastatic breast cancer.

Mathematical models have predicted that 7 days of capecitabine followed by 7 days of rest is an optimal dosing schedule for this drug and previous studies done al Memorial Sloan Kettering Cancer Center support the tolerability of this scheme.

This definitive, randomized trial comparing the efficacy of the new dosage with the conventional dosing schedule in patients with metastatic breast cancer is necessary and we hypothesize it will be superior in terms of efficacy.

Dosing schedules based on mathematical predictions for optimal drug delivery based on efficacy rather than toxicity could facilitate more rapid and economical drug development. This trial is a proof of principle trial of the highest priority.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 350
• Est. completion date: March 2019
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1 Subject Inclusion Criteria

• Informed consent has been obtained.

• Metastatic breast cancer.

• Measurable or non-measurable disease per RECIST criteria.

• Pathologic confirmation of breast cancer.

• No limit to the number of prior chemotherapy regimens permitted for metastatic disease.

• At least 3 weeks since prior chemotherapy. Patients should have recovered from all acute toxicity from such therapy (excluding alopecia).

• Age =18.

• ECOG 0-2

• Absolute Neutrophil Count (ANC )=1.0; hemoglobin =9, platelets

=75.000

• AST, ALT and Alkaline phosphatase <2.5x upper limit of normal (or <5x upper limit of normal in the case of liver metastases). Total bilirubin <1.5x upper limit of normal.

• Estimated creatinine clearance >50ml/min.

• If female of childbearing potential, pregnancy test is negative and the patient agrees to use an effective method to avoid pregnancy during the study.

Exclusion Criteria:

• HER2 over-expression and/or amplification as determined by immunohistochemistry (3+) or FISH (>2.0).

• No prior fluoropyrimidine in the metastatic setting. Adjuvant fluoropyrimidine is permitted if >12 months have elapsed since treatment.

• No restriction for prior hormonal therapy.

• GI malabsorption syndrome which could impair oral drug absorption.

• Concurrent use of warfarin is discouraged as drug interactions may make management of INR more difficult.

• Central nervous system metastases are permitted if previously treated or clinically stable for at least 3 months.

• Pregnant or nursing patients.

• Life expectancy <3 months.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Capecitabine
Two dosages comparison

Locations

Country	Name	City	State
Argentina	SLACOM	Buenos Aires

Sponsors (2)

Lead Sponsor	Collaborator
Latin American & Caribbean Society of Medical Oncology	Breast Cancer Research Foundation

Country where clinical trial is conducted

Argentina, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progress Free Survival (PFS)	The primary endpoint of this study is PFS, defined as the time from treatment start to progression or last date of follow-up. PFS will be estimated using Kaplan-Meier methods. This will be an intention to treat analysis. The Log-rank test will be used to test whether PFS is different for the two capecitabine schedules. It is hypothesized that the 7-7 schedule of capecitabine will have superior efficacy.	24 month
Secondary	Number of participants with toxicity.	Secondary Objectives: To assess and compare tolerability of the two capecitabine schedules in terms of selected hematologic and non-hematologic toxicities.; To compare the rates of grade 3 or greater diarrhea, nausea and vomiting between the two schedules.	24 month
Secondary	Number of patients with treatment delays.		24 month
Secondary	Number of patients with dose reduction.		24 month
Secondary	Number of patients with study withdrawal.		24 month